Connect with us

Hi, what are you looking for?

Friday, Sep 22, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

AI and Autonomy

AstraZeneca invests US$42M in Verge Genomics AI drug discovery platform

Following an initial investment, the deal could potentially be worth up to US$840 million plus royalties

AstraZeneca invests US$42M in Verge Genomics AI platform for rare disease drug discovery
Ireland's Prime Minister Leo Varadkar visits Alexion's College Park facility in Dublin last December. Photo via Alexion, a subsidiary of AstraZeneca

San Francisco’s biotechnology startup Verge Genomics, a drug discovery company utilizing an AI platform, has received its largest investment from Alexion — the rare disease branch of AstraZeneca plc (NASDAQ: AZN) (LON: AZN).

Verge announced the US$42 million investment and four-year agreement on Friday, which it says could potentially evolve into a deal valued at US$840 million plus royalties. The partnership will utilize Verge’s CONVERGE platform, which combines the power of machine learning with human tissue datasets from patients with different disorders to develop novel efficacious drugs.

Through the deal, Alexion will be selecting drug candidates discovered through the platform that show strong potential for treating different neurodegenerative and neuromuscular diseases and will have the option to develop, license and commercialize them.

Verge says its approach to drug discovery has been validated by its success in developing treatments for amyotrophic lateral sclerosis (ALS). The company announced positive safety and tolerability data for one of its ALS treatment drugs from a Phase I clinical trial in June and is also in the midst of developing different treatments for Parkinson’s.

Additionally, AstraZeneca will be taking an equity position in Verge alongside major investors such as the multi-trillion dollar investment firm BlackRock Inc (NYSE: BLK) and the Global Health Innovation Fund owned by the company’s first major pharmaceutical investor Merck & Co Inc (NYSE: MRK).

Read more: HumanFirst connects clinical researchers to vital data using artificial intelligence-based platform

Read more: Germany invests $2.3B to be world leader in artificial intelligence

“By leveraging Verge’s AI-enabled platform in combination with data from patient tissue samples, we see potential in helping researchers more efficiently identify and validate therapeutic targets for rare diseases,” said Seng H. Cheng, Senior Vice President, Head of Research and Product Development at Alexion.

Verge’s Chief Business Officer Jane Rhodes says the partnership will leverage the combined power of the company’s AI platform with Alexion’s expertise in developing and commercializing treatments for rare diseases.

“We believe that our work with Alexion will build on our achievements in central nervous system drug discovery and is indicative of the sustained interest from pharma in the potential of AI to transform drug discovery and development,” said Rhodes.

The vaccine manufacturer AstraZeneca invested €300 million in Alexion’s College Park pharmaceutical facility in Dublin in the fall of 2021.

Verge’s CEO Alice Zhang was recognized as one of Fortune magazine’s 40 under 40 business influencers last year. The company raised US$98 million in a series B funding round in December 2021.

AstraZeneca shares dropped by 2.4 per cent Monday to US$66.60 on the Nasdaq exchange.


Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AI and Autonomy

This is the largest acquisition the technology company has ever made and the sector's largest transaction this year

AI and Autonomy

The tech corporation is aiming to train 2 million people in its use by the end of 2026

AI and Autonomy

The program is meant to support healthcare professionals and speed up decisions regarding follow-ups or referrals

AI and Autonomy

The expanded partnership offers a scalable, cost-effective platform using NVIDIA technology to augment Infosys' Responsible AI Toolkit